Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults : a Danish population-based study. / Gjærde, Lars Klingen; Rank, Cecilie Utke; Andersen, Mette Klarskov; Jakobsen, Lasse Hjort; Sengeløv, Henrik; Olesen, Gitte; Kornblit, Brian; Marquart, Hanne; Friis, Lone Smidstrup; Petersen, Søren Lykke; Andersen, Niels Smedegaard; Nielsen, Ove Juul; Toft, Nina; Schjødt, Ida.
I: Leukemia and Lymphoma, Bind 63, Nr. 2, 2022, s. 416-425 .Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults
T2 - a Danish population-based study
AU - Gjærde, Lars Klingen
AU - Rank, Cecilie Utke
AU - Andersen, Mette Klarskov
AU - Jakobsen, Lasse Hjort
AU - Sengeløv, Henrik
AU - Olesen, Gitte
AU - Kornblit, Brian
AU - Marquart, Hanne
AU - Friis, Lone Smidstrup
AU - Petersen, Søren Lykke
AU - Andersen, Niels Smedegaard
AU - Nielsen, Ove Juul
AU - Toft, Nina
AU - Schjødt, Ida
N1 - Publisher Copyright: © 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000–2019. Patients had a median (min–max) age of 36 (18–74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27–66%) in year 2000 versus 77% (CI 59–88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00–1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93–1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87–0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93–1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.
AB - We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000–2019. Patients had a median (min–max) age of 36 (18–74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27–66%) in year 2000 versus 77% (CI 59–88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00–1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93–1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87–0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93–1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.
KW - acute lymphoblastic leukemia
KW - ALL
KW - allogeneic hematopoietic stem cell transplantation
KW - Allogeneic transplantation
KW - survival
U2 - 10.1080/10428194.2021.1992620
DO - 10.1080/10428194.2021.1992620
M3 - Journal article
C2 - 34672245
AN - SCOPUS:85117457557
VL - 63
SP - 416
EP - 425
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 2
ER -
ID: 288208331